Calvin Sandra, SVP and Chief Accounting Officer at Travere Therapeutics ($TVTX), sold nearly 3 million dollars worth of company shares in four open market transactions over the last year. Her most recent sale occurred on February 3, 2026. These sales rank her 2,756th among 11,678 individual insiders by total value sold, below the average of 8.6 million dollars per insider and 6.4 transactions. Sandra made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Employee stock option (right to buy) | 20160 | $0.00 | 20,160.0000 | 89,211,813 | 9999.99% | 0.02% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Common Stock | 15180 | $0.00 | 53,413.0000 | 89,211,813 | 39.70% | 0.02% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 4333 | $32.12 | 49,080.0000 | 89,211,813 | 8.11% | 0.00% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 7402 | $40.00 | 38,233.0000 | 102,618,560 | 16.22% | 0.01% |
| Dec. 15, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 2910 | $36.00 | 45,635.0000 | 102,618,560 | 5.99% | 0.00% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 17500 | $0.00 | 0.0000 | 102,618,560 | 100.00% | 0.02% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 10000 | $0.00 | 0.0000 | 102,618,560 | 100.00% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 67115 | $36.00 | 48,545.0000 | 102,618,560 | 58.03% | 0.07% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 6250 | $8.93 | 115,660.0000 | 102,618,560 | 5.71% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 12500 | $22.40 | 109,410.0000 | 102,618,560 | 12.90% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 15000 | $0.00 | 2,500.0000 | 102,618,560 | 85.71% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 17500 | $26.88 | 81,910.0000 | 102,618,560 | 27.17% | 0.02% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 10000 | $25.25 | 64,410.0000 | 102,618,560 | 18.38% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 12500 | $0.00 | 7,500.0000 | 102,618,560 | 62.50% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 6250 | $0.00 | 18,750.0000 | 102,618,560 | 25.00% | 0.01% |
| Nov. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 15000 | $27.50 | 96,910.0000 | 102,618,560 | 18.31% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 10000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 10000 | $25.00 | 63,654.0000 | 78,888,861 | 13.58% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 10000 | $17.44 | 73,654.0000 | 78,888,861 | 15.71% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 10000 | $25.00 | 63,654.0000 | 78,888,861 | 13.58% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 10000 | $17.96 | 73,654.0000 | 78,888,861 | 15.71% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 10000 | $25.00 | 63,654.0000 | 78,888,861 | 13.58% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 15000 | $15.46 | 78,654.0000 | 78,888,861 | 23.56% | 0.02% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 15000 | $25.00 | 63,654.0000 | 78,888,861 | 19.07% | 0.02% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 9244 | $25.00 | 54,410.0000 | 78,888,861 | 14.52% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 10000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 10000 | $16.23 | 73,654.0000 | 78,888,861 | 15.71% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 10000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 15000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.02% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Employee stock option (right to buy) | 26000 | $0.00 | 26,000.0000 | 78,888,861 | 9999.99% | 0.03% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Common Stock | 13000 | $0.00 | 67,002.0000 | 78,888,861 | 24.07% | 0.02% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 3348 | $20.12 | 63,654.0000 | 78,888,861 | 5.00% | 0.00% |
| Jan. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 925 | $18.94 | 54,002.0000 | 78,888,861 | 1.68% | 0.00% |
| Dec. 26, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 15000 | $12.67 | 69,927.0000 | 77,779,379 | 27.31% | 0.02% |
| Dec. 26, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 15000 | $0.00 | 0.0000 | 77,779,379 | 100.00% | 0.02% |
| Dec. 26, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 15000 | $17.22 | 54,927.0000 | 77,779,379 | 21.45% | 0.02% |
| Nov. 25, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Common Stock | 15000 | $12.67 | 67,017.0000 | 77,779,379 | 28.84% | 0.02% |
| Nov. 25, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | M | Employee stock option (right to buy) | 15000 | $0.00 | 15,000.0000 | 77,779,379 | 50.00% | 0.02% |
| Nov. 25, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 12090 | $18.30 | 54,927.0000 | 77,779,379 | 18.04% | 0.02% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Common Stock | 12500 | $0.00 | 53,837.0000 | 74,267,418 | 30.24% | 0.02% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Common Stock | 1000 | $0.00 | 54,837.0000 | 74,267,418 | 1.86% | 0.00% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 2820 | $8.53 | 52,017.0000 | 74,267,418 | 5.14% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | A | Employee stock option (right to buy) | 25000 | $0.00 | 25,000.0000 | 74,267,418 | 9999.99% | 0.03% |
| Jan. 23, 2024 | Travere Therapeutics, Inc. | $TVTX | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | S | Common Stock | 910 | $9.07 | 41,337.0000 | 74,267,418 | 2.15% | 0.00% |